Can a Four-Drug combo erase Triple-Negative breast cancer before surgery?
NCT ID NCT06910072
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to see how many achieve a pathological complete response (no cancer cells left in the removed tissue). The study also tracks side effects and long-term outcomes like event-free survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A combination of chemotherapy (paclitaxel polymeric micelles and carboplatin) and two immunotherapy drugs (iparomilimab and tuvonralimab) given before surgery.
- What this could lead to
- If successful, this approach could increase the chance of eliminating the tumor before surgery, potentially improving long-term outcomes for people with triple-negative breast cancer.
- What could go wrong
- This is an early-phase study with a small number of participants, so results may not be conclusive. The combination may cause significant side effects, and the benefit over standard treatment is not yet proven.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOADJUVANT THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Custom-Made vaccine outsmart Triple-Negative breast cancer?
- Can a drug combo outsmart a tough breast cancer subtype?
- Can a new drug combo outsmart triple-negative breast cancer?
- Can your own immune cells fight advanced cancer?
- Can a biomarker spare breast cancer patients from harsh chemo?
- Can an immunotherapy drug boost chemotherapy's power against a tough breast cancer?